Welcome to our dedicated page for Blackrock SEC filings (Ticker: BLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for BlackRock, Inc. (NYSE: BLK), a global asset manager and financial technology provider classified in the finance and insurance sector under investment banking and securities dealing. These filings offer detailed information about BlackRock’s financial results, corporate actions, securities listings, and other material events.
Recent Form 8-K filings show how BlackRock reports quarterly and annual earnings. For example, filings dated January 15, 2026, October 14, 2025, and July 15, 2025 state that the company reported results of operations for specific periods and furnished earnings releases and supplemental materials as exhibits. They also note investor conference calls and webcasts where management discusses these results. Investors can review these documents to understand revenue drivers, expenses, and other aspects of BlackRock’s financial condition as disclosed in the attached materials.
Filings also document corporate transactions and capital structure details. A Form 8-K filed on July 1, 2025 describes the completion of BlackRock’s acquisition of 100% of the business and assets of HPS Investment Partners, characterized as a leading global credit investment manager. The filing explains the issuance of units in a BlackRock subsidiary that are exchangeable into BlackRock common stock, as well as restricted stock units and potential contingent consideration tied to post-closing performance. Another filing lists BlackRock’s securities registered under Section 12(b) of the Exchange Act, including its common stock (BLK) and 3.750% Notes due 2035 (BLK 35), both traded on the New York Stock Exchange.
Through this filings page, users can follow ongoing disclosure related to BlackRock’s operations, acquisitions, financing arrangements, and governance matters as reported to the U.S. Securities and Exchange Commission. Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that help explain the structure and implications of filings such as 8-Ks, annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4, making it easier to interpret complex regulatory documents.
BlackRock, Inc. has filed an amended Schedule 13G reporting a large passive stake in Arrowhead Pharmaceuticals Inc.. As of 12/31/2025, BlackRock reports beneficial ownership of 20,323,221 shares of Arrowhead common stock, representing 15.0% of the outstanding class. BlackRock has sole voting power over 20,124,285 shares and sole dispositive power over 20,323,221 shares, with no shared voting or dispositive power.
The filing aggregates holdings across certain BlackRock business units and notes that one holder, iShares Core S&P Small-Cap ETF, on its own holds more than five percent of Arrowhead’s common stock. BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrowhead.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in ACRES COMMERCIAL REALTY CORP common stock as of 12/31/2025. BlackRock reports beneficial ownership of 466,499 shares, representing 6.4% of the outstanding common stock. It holds sole voting power over 461,048 shares and sole dispositive power over 466,499 shares, with no shared voting or dispositive authority.
The filing explains that these shares are held by certain BlackRock business units on behalf of various underlying clients, and that no single other person has an interest exceeding five percent of the class. BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
BlackRock, Inc. has filed a Schedule 13G reporting a significant passive ownership position in Bentley Systems Inc. Class B stock. BlackRock reports beneficial ownership of 19,138,817 Class B shares, representing 6.6% of the class. It has sole voting power over 18,208,036 shares and sole dispositive power over 19,138,817 shares, with no shared voting or dispositive power.
The filing explains that these holdings reflect securities beneficially owned by certain BlackRock business units, and that the position is held in the ordinary course of business. BlackRock certifies that the shares were not acquired for the purpose of changing or influencing control of Bentley Systems. The statement is signed by Spencer Fleming, Managing Director of BlackRock, Inc.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of Cogent Biosciences, Inc. common stock. As of December 31, 2025, BlackRock reports beneficial ownership of 11,370,224 shares, representing 6.5% of Cogent’s outstanding common stock. It has sole voting power over 11,184,653 shares and sole dispositive power over 11,370,224 shares, with no shared voting or dispositive power.
The filing explains that these holdings reflect securities beneficially owned by certain BlackRock business units, with other units disaggregated. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Cogent’s common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Cogent Biosciences.
Compass Therapeutics, Inc. (CMPX) reported that BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in the company’s common stock. BlackRock reports beneficial ownership of 9,271,644 shares of Compass Therapeutics common stock, representing 5.2% of the outstanding class as of the reported date.
BlackRock has sole voting power over 9,138,337 shares and sole dispositive power over 9,271,644 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and are not intended to change or influence control of Compass Therapeutics. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single one has more than five percent of the total outstanding shares.
BlackRock, Inc. has filed an amended ownership report showing that it beneficially owns 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, representing 4.6% of the outstanding class as of the event date. BlackRock reports sole voting power over 3,584,479 shares and sole dispositive power over 3,625,824 shares, with no shared voting or dispositive power.
The filing states that these securities are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals. The filing also notes that various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Eledon’s total outstanding common shares.
BlackRock, Inc. filed an amended Schedule 13G reporting a significant ownership stake in Ares Management Corporation Class A stock as of 12/31/2025. BlackRock reports beneficial ownership of 15,778,507 Class A shares, representing 7.2% of the class. It has sole power to vote 14,563,674 shares and sole power to dispose of 15,778,507 shares, with no shared voting or dispositive power.
The filing states that various underlying clients or investors have rights to dividends or sale proceeds, but no single other person has more than five percent of the outstanding common shares. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ares Management Corporation.
An insider has filed a notice of proposed sale of 27,047 shares of common stock, to be sold through Merrill Lynch, Pierce, Fenner & Smith Inc. on the NYSE. The filing lists an aggregate market value for these shares of 31,675,638.98, against a total of 163,138,922 shares outstanding for the issuer. The shares to be sold were acquired on 01/16/2026 via the exercise of employee stock options, with payment described as an option exercise on the same date. The document also notes that Martin Small sold 1,258 common shares on 12/01/2025, generating 1,311,263.72 in gross proceeds. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
BlackRock, Inc. reported that its board’s Management Development and Compensation Committee has adopted a new carry-based incentive plan called the Executive Carry Program (ECP) for selected senior executives other than the Chief Executive Officer. Under the ECP, eligible executives may receive a percentage of future carry distributions from a pool of BlackRock’s flagship private markets funds across asset classes such as infrastructure, private debt, private equity and real estate.
The awards are entirely pay-for-performance, providing no value at grant and paying out only if the underlying funds generate carry distributions based on specified long-term performance returns. Awards are granted through an aggregator partnership and exclude any carry value accrued before the grant date. Each award vests over five years with no vesting until the third anniversary, then one-third vesting on each of the third, fourth and fifth anniversaries, subject to continued service and restrictive covenants.
Unvested awards are generally forfeited upon termination, with limited continued vesting or acceleration in cases such as involuntary termination without cause, qualified retirement, death or disability. The program also incorporates holdback and clawback features tied to ultimate fund performance and BlackRock’s existing clawback and recoupment policies.
BlackRock, Inc. filed a current report to note that it has reported results of operations for the three months and year ended December 31, 2025. The company issued an earnings release, which is included as Exhibit 99.1.
The filing also explains that BlackRock will hold an investor conference call and webcast on January 15, 2026 to discuss these earnings results, using supplemental materials furnished as Exhibit 99.2. The report is signed on behalf of the company by its Chief Financial Officer, Martin S. Small.